Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes
- 1 November 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (11) , 2055-2060
- https://doi.org/10.1128/aac.34.11.2055
Abstract
Cryptococcosis is an opportunistic infection that is responsible for increased morbidity and mortality in patients with the acquired immunodeficiency syndrome. The high toxicity of the antifungal agent that is mainly used against cryptococcosis, amphotericin B (AMB), accounts for the need for new treatments, especially in patients with the acquired immunodeficiency syndrome because of the high relapse rate of cryptococcosis. Drug targeting may be one of these alternate treatments. Since we have demonstrated that an immunoglobulin G1 (IgG1) anti-Cryptococcus neoformans serotype A monoclonal antibody (E1) was protective during experimental cryptococcosis in mice, we investigated whether specific targeting of AMB with liposomes that bear E1 would improve the therapeutic index of the drug. For that purpose, in vitro and in vivo experiments were designed to compare the specificities and activities of these liposomes with those of control immunoliposomes bearing a nonrelated IgG1 monoclonal antibody (CY34). The immunoliposomes were prepared by covalently linking E1 or CY34 and small unilamellar vesicles. When immunoliposomes were incubated with yeast cells, only E1-bearing liposomes recognized C. neoformans. In vivo, mice that were treated 24 h after infection with one injection of AMB (0.12 mg/kg of body weight) intercalated into E1-bearing liposomes survived significantly longer than did those given the same dose of AMB alone or AMB intercalated into nontargeted liposomes or control immunoliposomes. None of the mice that were given control treatments did statistically better than those that were given AMB. Keeping in mind that this kind of therapy requires knowledge of the antigenic type of the infecting organism, the results suggest that specific targeting of small doses of AMB improve the efficacy of AMB and might be an alternative to the use of larger doses of AMB.This publication has 39 references indexed in Scilit:
- Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to Candida albicansJournal of Medical Microbiology, 1989
- Cryptococcal Meningitis in Patients with AIDSThe Journal of Infectious Diseases, 1988
- Effects of Antifungal Agents and Interferon on Macrophage Cytotoxicity for Fungi and Tumor CellsThe Journal of Infectious Diseases, 1987
- Liposomal Amphotericin B for the Treatment of Systemic Fungal Infections in Patients with Cancer: A Preliminary StudyThe Journal of Infectious Diseases, 1985
- Liposomes as drug carriers in cancer chemotherapyPharmacology & Therapeutics, 1984
- Liposome-Encapsulated Amphotericin B for Treatment of Disseminated Candidiasis in Neutropenic MiceThe Journal of Infectious Diseases, 1984
- Altered Tissue Distribution of Amphotericin B by Liposomal Encapsulation: Comparison of Normal Mice to Mice Infected with Candida albicansCancer Drug Delivery, 1984
- Treatment and Prophylaxis of Disseminated Infection Due to Candida albicans in Mice with Liposome-Encapsulated Amphotericin BThe Journal of Infectious Diseases, 1983
- Monoclonal antibody covalently coupled to liposomes: Specific targeting to cellsJournal of Supramolecular Structure and Cellular Biochemistry, 1981
- Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein ANature, 1980